172 related articles for article (PubMed ID: 34510663)
21. Computational analysis of image-based drug profiling predicts synergistic drug combinations: applications in triple-negative breast cancer.
Brandl MB; Pasquier E; Li F; Beck D; Zhang S; Zhao H; Kavallaris M; Wong ST
Mol Oncol; 2014 Dec; 8(8):1548-60. PubMed ID: 24997502
[TBL] [Abstract][Full Text] [Related]
22. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
Zhao B; He T
Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499
[TBL] [Abstract][Full Text] [Related]
23. Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes.
Beer TM; Goldman B; Synold TW; Ryan CW; Vasist LS; Van Veldhuizen PJ; Dakhil SR; Lara PN; Drelichman A; Hussain MH; Crawford ED
Clin Genitourin Cancer; 2008 Sep; 6(2):103-9. PubMed ID: 18824433
[TBL] [Abstract][Full Text] [Related]
24. Eg5 Inhibitors Have Contrasting Effects on Microtubule Stability and Metaphase Spindle Integrity.
Chen GY; Kang YJ; Gayek AS; Youyen W; Tüzel E; Ohi R; Hancock WO
ACS Chem Biol; 2017 Apr; 12(4):1038-1046. PubMed ID: 28165699
[TBL] [Abstract][Full Text] [Related]
25. A potent chemotherapeutic strategy for bladder cancer: (S)-methoxy-trityl-L-cystein, a novel Eg5 inhibitor.
Ding S; Nishizawa K; Kobayashi T; Oishi S; Lv J; Fujii N; Ogawa O; Nishiyama H
J Urol; 2010 Sep; 184(3):1175-81. PubMed ID: 20663523
[TBL] [Abstract][Full Text] [Related]
26. Functional genetic screens identify genes essential for tumor cell survival in head and neck and lung cancer.
Martens-de Kemp SR; Nagel R; Stigter-van Walsum M; van der Meulen IH; van Beusechem VW; Braakhuis BJ; Brakenhoff RH
Clin Cancer Res; 2013 Apr; 19(8):1994-2003. PubMed ID: 23444224
[TBL] [Abstract][Full Text] [Related]
27.
Shao YY; Sun NY; Jeng YM; Wu YM; Hsu C; Hsu CH; Hsu HC; Cheng AL; Lin ZZ
Cells; 2021 Jul; 10(7):. PubMed ID: 34359867
[TBL] [Abstract][Full Text] [Related]
28. STLC-resistant cell lines as tools to classify chemically divergent Eg5 targeting agents according to their mode of action and target specificity.
Indorato RL; DeBonis S; Kozielski F; Garcia-Saez I; Skoufias DA
Biochem Pharmacol; 2013 Nov; 86(10):1441-51. PubMed ID: 24041742
[TBL] [Abstract][Full Text] [Related]
29. Effects of evodiamine on PI3K/Akt and MAPK/ERK signaling pathways in pancreatic cancer cells.
Hong Z; Wang Z; Zhou B; Wang J; Tong H; Liao Y; Zheng P; Jamshed MB; Zhang Q; Chen H
Int J Oncol; 2020 Mar; 56(3):783-793. PubMed ID: 31922213
[TBL] [Abstract][Full Text] [Related]
30. Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents.
El-Nassan HB
Eur J Med Chem; 2013 Apr; 62():614-31. PubMed ID: 23434636
[TBL] [Abstract][Full Text] [Related]
31. In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities.
DeBonis S; Skoufias DA; Lebeau L; Lopez R; Robin G; Margolis RL; Wade RH; Kozielski F
Mol Cancer Ther; 2004 Sep; 3(9):1079-90. PubMed ID: 15367702
[TBL] [Abstract][Full Text] [Related]
32. Mechanism of inhibition of human KSP by ispinesib.
Lad L; Luo L; Carson JD; Wood KW; Hartman JJ; Copeland RA; Sakowicz R
Biochemistry; 2008 Mar; 47(11):3576-85. PubMed ID: 18290633
[TBL] [Abstract][Full Text] [Related]
33. KIF11 inhibition for glioblastoma treatment: reason to hope or a struggle with the brain?
Valensin S; Ghiron C; Lamanna C; Kremer A; Rossi M; Ferruzzi P; Nievo M; Bakker A
BMC Cancer; 2009 Jun; 9():196. PubMed ID: 19545421
[TBL] [Abstract][Full Text] [Related]
34. Structure-activity relationship of S-trityl-L-cysteine analogues as inhibitors of the human mitotic kinesin Eg5.
Debonis S; Skoufias DA; Indorato RL; Liger F; Marquet B; Laggner C; Joseph B; Kozielski F
J Med Chem; 2008 Mar; 51(5):1115-25. PubMed ID: 18266314
[TBL] [Abstract][Full Text] [Related]
35. Significant decrease of ADP release rate underlies the potent activity of dimethylenastron to inhibit mitotic kinesin Eg5 and cancer cell proliferation.
Sun L; Sun X; Xie S; Yu H; Zhong D
Biochem Biophys Res Commun; 2014 May; 447(3):465-70. PubMed ID: 24732354
[TBL] [Abstract][Full Text] [Related]
36. Eg5 targeting agents: From new anti-mitotic based inhibitor discovery to cancer therapy and resistance.
Garcia-Saez I; Skoufias DA
Biochem Pharmacol; 2021 Feb; 184():114364. PubMed ID: 33310050
[TBL] [Abstract][Full Text] [Related]
37. Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner.
Zhao H; Wei R; Wang L; Tian Q; Tao M; Ke J; Liu Y; Hou W; Zhang L; Yang J; Hong T
Am J Physiol Endocrinol Metab; 2014 Jun; 306(12):E1431-41. PubMed ID: 24801389
[TBL] [Abstract][Full Text] [Related]
38. Bufalin inhibits pancreatic cancer by inducing cell cycle arrest via the c-Myc/NF-κB pathway.
Liu X; Xiao XY; Shou QY; Yan JF; Chen L; Fu HY; Wang JC
J Ethnopharmacol; 2016 Dec; 193():538-545. PubMed ID: 27686271
[TBL] [Abstract][Full Text] [Related]
39. Designing and developing S100P inhibitor 5-methyl cromolyn for pancreatic cancer therapy.
Arumugam T; Ramachandran V; Sun D; Peng Z; Pal A; Maxwell DS; Bornmann WG; Logsdon CD
Mol Cancer Ther; 2013 May; 12(5):654-62. PubMed ID: 23303403
[TBL] [Abstract][Full Text] [Related]
40. Kinesin Eg5 Targeting Inhibitors as a New Strategy for Gastric Adenocarcinoma Treatment.
Marconi GD; Carradori S; Ricci A; Guglielmi P; Cataldi A; Zara S
Molecules; 2019 Oct; 24(21):. PubMed ID: 31683688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
